Sorafenat 200mg Tablet

Sorafenib 200mg Tablet may cause certain side effects. Make sure to contact your healthcare professional if side effects occur after administration or last longer than usual.

• Diarrhea 
• Hand-foot skin reaction (painful blisters)
• Fatigue
• Hair loss
• Weight loss
• Rash
• Abdominal pain 
• Nausea
• Loss of appetite
• Hypertension

​Take Sorafenib 200mg Tablet orally on an empty stomach once a day. Try not to miss your regular dosing schedule. Take this medicine as prescribed by your medical advisor. Do not crush or chew the tablet. The dose is decided by a medical advisor according to your response to the treatment and your previous medical condition. Regular monitoring of blood pressure is required during treatment with this medicine. Keep yourself hydrated and maintain good nutrition while taking this medicine. 

• Sorafenat is a kinase inhibitor that decreases tumor cell proliferation in vitro.
• Sorafenat inhibited the tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice.
• Reductions in tumor angiogenesis were seen in models of HCC and RCC upon Sorafenat treatment, and increases in tumor apoptosis were observed in models of HCC, RCC, and DTC. 
  

It is advisable not to miss a dose. If you miss a scheduled dose of the Sorafenat tablet, contact your doctor immediately. 

• Pharmacokinetic and pharmacodynamic characteristics of sorafenib 200mg film‑coated tablets (sorafenat). (n.d.). Absorption, metabolism, and elimination profiles. medthority.com and PMC article summary.
• Study 100554 (SHARP trial) and Study 11849: sorafenib versus placebo in hepatocellular carcinoma and renal cell carcinoma. (n.d.). Summary of product characteristics and pivotal trial data publications. medicines.org.uk [SmPC & EMA summary].
• Suk, F. M., Wu, C. Y., Fang, C. C., Chen, T. L., & Liao, Y. J. (2023, August 9). β‑HB treatment reverses sorafenib resistance by shifting glycolysis‑lactate metabolism in HCC. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2023.115293
• TARGET Phase III trial: sorafenib in advanced renal cell carcinoma. (n.d.). Trial summary data reporting median PFS, OS, and hazard ratios. medicines.org.uk [SmPC & EMA summary].